gas pain tirzepatide Side Effects: How Zepbound & Mounjaro Affect Digestion How to Remove Trapped Gas

However, a new peptide is revolutionizing results for anyone struggling with weight loss or diabetic health issues

Take a closer look at the clinical trials we did for our gut health supplements to learn more about whats possible with res

#Camurus #CAM2056 #GLP1 #Semaglutide #Wegovy #Obesity #Diabetes #LongActingInjection #MetabolicHealth Camurus Reports Positive Phase 1b Results for CAM2056 a Monthly Depot Version of Semaglutide | Presented at ObesityWeek 2025 Key Highlights: In a randomized Phase 1b study (n80 adults with overweight/obesity), CAM2056 (two biweekly initiation + two monthly doses) achieved: Up to 9.3% weight loss vs 5.2% for weekly semaglutide (Wegovy) A1c reduction 0.44% vs 0.32% for weekly semaglutide by Day 85 Matched 3-month weight loss seen with weekly semaglutide at 5 months Safety/tolerability consistent with weekly formulation mild, transient injection-site reactions even with rapid dose escalation Developed using Camuruss FluidCrystal long-acting depot technology Why It Matters: Patient convenience & adherence: Monthly dosing could significantly reduce treatment burden and enhance compliance offering an edge over biosimilars and weekly GLP-1s

Shown to support up to 22% weight loss in clinical studies, higher than Semaglutide Not recommended for individuals with a history of medullary thyroid cancer or pancreatitis